Kuhn Annegret, Beissert Stefan, Krammer Peter H
Division of Immunogenetics, Tumor Immunology Program, German Cancer Research Center, Heidelberg, Germany.
Arch Dermatol Res. 2009 Jan;301(1):71-81. doi: 10.1007/s00403-008-0891-9. Epub 2008 Nov 5.
Natural CD4(+)CD25(+) regulatory T cells (T(reg)) show a potent immunosuppressive function and contribute to immunologic self-tolerance by suppressing potentially auto-reactive T cells. Depletion of these cells leads to the induction of severe autoimmune diseases in animal models; more recently, several studies have also reported an impairment of T(reg) number and/or function in various human autoimmune diseases. For example, aberrant numbers of circulating CD4(+)CD25(+) T(reg) have been seen in patients with type I diabetes, mycosis fungoides, graft-versus-host-reaction, and rheumatoid arthritis. Moreover, increased numbers of functionally active CD4(+)CD25(+) T(reg) have been detected in the synovial fluid of patients with rheumatoid arthritis. In systemic lupus erythematosus (SLE), conflicting data on the role of CD4(+)CD25(+) T(reg) in human autoimmune diseases have been presented in the literature. Decreased numbers of peripheral blood T(reg) have been reported by most studies on SLE patients with active disease, but non-impaired or even increased CD4(+)CD25(+) T(reg) numbers have also been described. In addition, both deficient and normal suppressive capacity of isolated T(reg) have been observed in SLE. Analysis of CD4(+)FoxP3(+) T(reg) in skin lesions of patients with a primarily cutaneous manifestation of the disease showed a significant reduction in cell numbers as compared to other inflammatory skin diseases, suggesting the importance of analyzing T(reg) numbers in the affected tissue. In this review, we discuss the role of CD4(+)CD25(+) T(reg) in autoimmunity and recent published data on SLE. Furthermore, we highlight the need for additional studies that address specific gaps of knowledge regarding the pathophysiological mechanisms as well as the identification of future therapeutic strategies for autoimmune diseases.
天然CD4(+)CD25(+)调节性T细胞(T(reg))具有强大的免疫抑制功能,通过抑制潜在的自身反应性T细胞来促进免疫自我耐受。在动物模型中,这些细胞的耗竭会导致严重自身免疫性疾病的诱发;最近,多项研究还报道了在各种人类自身免疫性疾病中T(reg)数量和/或功能的受损。例如,在1型糖尿病、蕈样肉芽肿、移植物抗宿主反应和类风湿性关节炎患者中,已观察到循环CD4(+)CD25(+) T(reg)数量异常。此外,在类风湿性关节炎患者的滑液中检测到功能活跃的CD4(+)CD25(+) T(reg)数量增加。在系统性红斑狼疮(SLE)中,文献中关于CD4(+)CD25(+) T(reg)在人类自身免疫性疾病中的作用存在相互矛盾的数据。大多数关于活动期SLE患者的研究报告外周血T(reg)数量减少,但也有报道称CD4(+)CD25(+) T(reg)数量未受损甚至增加。此外,在SLE中还观察到分离出的T(reg)抑制能力既有缺陷又正常。对该疾病主要皮肤表现患者皮肤病变中的CD4(+)FoxP3(+) T(reg)分析显示,与其他炎症性皮肤病相比,细胞数量显著减少,这表明分析受累组织中T(reg)数量的重要性。在本综述中,我们讨论了CD4(+)CD25(+) T(reg)在自身免疫中的作用以及最近发表的关于SLE的数据。此外,我们强调需要进行更多研究,以填补关于病理生理机制的特定知识空白,并确定自身免疫性疾病的未来治疗策略。